Company intelligence / Profile preview

Nordic Pharma, Inc.

Berwyn, Pennsylvania, United Statesnordicpharmausa.com ↗

Ownership: Private
Employees: ~23
Development stage: Commercial

Overview

The company has a portfolio of generic and branded medications. Their lead product AMZ002 (a purified synthetic polypeptide) entered Phase III clinical trials for infantile epileptic disease. They recently acquired LACRIFILL canalicular gel for Dry Eye Disease, which is FDA-cleared and scheduled for U.S. launch in Q2 2024.[2][6][7]

Therapeutic areas: OphthalmologyNeurology
Modalities: Small moleculespolypeptidesmedical devices
Industry: Biotech

Drug pipeline

1 asset

LACRIFILL

Commercial

Indications: Dry eye disease

Partnerships

Amzell, B.V. (for AMZ002 development)

Beyond the preview

Go deeper on Nordic Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nordic Pharma, Inc..

Explore the full profile